

Editorial

Advancing Cell Therapy Through Scientific Excellence and Interdisciplinary Innovation

Christian Jorgensen

Institute for Regenerative Medicine and Biotherapy (IRMB), INSERM U1183, Saint Eloi Hospital, CHRU Montpellier, 34090 Montpellier, France; c-jorgensen@chu-montpellier.fr

Received: 25 August 2026; Accepted: 7 September 2026; Published: 23 September 2026

How To Cite: Jorgensen, C. Advancing Cell Therapy Through Scientific Excellence and Interdisciplinary Innovation. *Stem Cells & Advanced Cell Therapy* **2026**, *1*(1), 1.

The field of cell therapy is undergoing an unprecedented transformation. Scientific discoveries that once required decades to mature are now progressing within a few years, driven by remarkable advances in stem cell biology, genome engineering, regenerative medicine, computational biology, and artificial intelligence. This acceleration is redefining the boundaries of biomedical research and creating entirely new therapeutic opportunities for patients suffering from cancer, autoimmune disorders, degenerative diseases, and many other unmet medical conditions.

It is in this rapidly evolving landscape that we are proud to launch this new international journal dedicated to cell therapy and regenerative medicine.

Our ambition is founded on three fundamental principles:

- First, scientific excellence begins with rigorous and constructive peer review. The credibility of scientific progress depends on the quality, fairness, and transparency of the evaluation process. Our editorial policy is committed to providing authors with timely, objective, and expert reviews that not only ensure scientific rigor but also improve the quality of submitted manuscripts. We welcome original research articles, innovative technological developments, translational studies, early clinical investigations, and interdisciplinary contributions that bridge traditional disciplinary boundaries. The complexity of modern cell therapies requires close interactions between cell biology, immunology, bioengineering, biomaterials, computational sciences, clinical medicine, manufacturing, regulatory sciences, and biostatistics. Our journal aims to become a forum where these disciplines converge.
- Second, artificial intelligence is profoundly changing the way biomedical research is conducted. AI-powered approaches are accelerating the analysis of multi-omics datasets, imaging, single-cell technologies, biomarker discovery, therapeutic target identification, and the design of engineered cells. Combined with automation and high-throughput experimentation, these technologies are dramatically increasing the volume and complexity of scientific data. This new space of discovery creates an urgent need for publishing platforms capable of rapidly disseminating robust, reproducible, and interdisciplinary research. Our journal seeks to provide such a platform while maintaining the highest standards of scientific integrity. We particularly encourage studies integrating AI with experimental biology, manufacturing optimization, clinical decision support, and precision cell therapies.
- Third, the extraordinary expansion of cell-based therapeutics justifies a broad and inclusive scientific scope. Cell therapy is no longer confined to a single discipline but encompasses a continuum of innovations extending from fundamental biology to clinical implementation. Our journal welcomes research covering stem cell biology, induced pluripotent stem cells (iPSCs), tissue engineering, regenerative medicine, organoids, extracellular vesicles, gene editing technologies, advanced biomanufacturing, and cell engineering. We also recognize the revolutionary impact of immune cell therapies, including CAR-T cells, CAR-NK cells, engineered macrophages, regulatory T-cell therapies, T-cell receptor engineering, and next-generation immune cell platforms. By embracing this diversity, we aim to foster dialogue between researchers



developing regenerative approaches and those advancing immune-based therapies, two fields that increasingly share common technologies and translational challenges.

Ultimately, the success of the *Journal of Stem Cells and Advanced Cell Based Therapy* will depend on the commitment of its scientific community. We invite researchers, clinicians, engineers, data scientists, and industry innovators from around the world to contribute their best work. Together, we can accelerate the translation of fundamental discoveries into safe, effective, and accessible therapies that improve patients' lives.

We envision this journal as more than a publication venue. It will be a collaborative international community dedicated to scientific excellence, interdisciplinary innovation, and the responsible advancement of cell therapies for the benefit of global health.

Conflicts of Interest

The authors declare no conflict of interest.

Use of AI and AI-Assisted Technologies

No AI tools were utilized for this paper.